This phase II trial is assessing the combination of an immunotherapy drug (Avelumab) and stereotactic ablative body radiotherapy (SABR) for the treatment of castrate-resistant prostate cancer.
This trial is treating patients with castrate-resistant prostate cancer.
This is a radiotherapy and systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS)
This is a non-randomised trial. Patients enrolled in this trial will receive a single fraction of 20 Gy to 1-2 metastases (bone and/or lymph node) with the location of sites selected at the discretion of the treating radiation oncologist. This will be followed by Avelumab commencing within 5 days +/- 3 days of SABR. After completing cycle 1 of Avelumab, patients will receive a second course of treatment with SABR to 1-2 different metastases for 5 days +/-3 days.
Recruiting Hospitals Read More